OSTX AMEX
OS Therapies Incorporated
1W: -1.8%
1M: -4.7%
3M: +1.2%
YTD: +21.6%
1Y: -18.5%
$1.62
+0.01 (+0.62%)
Weekly Expected Move ±7.2%
$1
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2024-11-01
Earliest Filing
2026-04-02
Latest Filing
acquirer: 2
partner: 1
investor: 1
Counterparties (Filed by OSTX)
4 relationshipsCompanies named in OSTX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Ceros Financial Services, Inc. | — | partner | Placement agent for the registered direct offering of common stock and warrants. | 2026-04-02 | View |
| Ayala Pharmaceuticals, Inc. | — | acquirer | Acquired HER2 Assets and intellectual property from OS Therapies Incorporated. | 2025-04-15 | View |
| Ayala Pharmaceuticals, Inc. | — | acquirer | Acquired HER2 and Listeria monocytogenes intellectual property assets from OS Therapies Incorporated. | 2025-01-29 | View |
| Square Gate Capital Master Fund, LLC-Series 3 | — | investor | OS Therapies entered into an Equity Purchase Agreement to sell up to $15M of common stock to this investor. | 2024-11-01 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-10 | Other Events; Exhibits | View | |
| 2026-09-09 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-08-21 | Material Agreement; Exhibits | Agreement | View |
| 2026-08-12 | Material Agreement; Financial Obligation; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-08-06 | Material Agreement; Financial Obligation; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-07-29 | Termination of Agreement | View | |
| 2026-07-07 | Exhibits | View | |
| 2026-07-02 | Material Agreement; Financial Obligation; Unregistered Equity Sales; Officer/Director Change; Other | Agreement | View |
| 2026-04-30 | Regulation FD; Exhibits | View | |
| 2026-04-02 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-03-31 | Other Events; Exhibits | View | |
| 2026-03-06 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2026-02-13 | Other Events | View | |
| 2026-01-12 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2025-10-21 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-10-17 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-09-30 | Other Events; Financial Statements and Exhibits | View | |
| 2025-09-02 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2025-08-26 | Termination of Material Definitive Agreement; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-19 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR